The U.S. Food and Drug Administration has approved Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous…
Continue Reading
News Source: medicalxpress.com
FDA approves Dupixent for chronic spontaneous urticaria in young children
Leave a Reply